Update Biomeds Alert-POSC....Pressed Released Special Report Coming on Friday.
After telling investors, "We believe Positron's (OTCBB:POSC) dose dispensing device will revolutionize the way radiopharmaceuticals are compounded and distributed in the US and around the world." BiomedReports will feature a fully press-released special report and interview on the subject with Positron's CEO, Patrick Rooney this Friday.
BiomedReports today has learned that not only one, but multiple big board companies may have apparently taken great interest in POSC's Nuclear Pharm-Assist® technology and that some may have already inked deals involving the platform with the company.
While everyone has been focused on POSC's bright future as the leader and single buggest provider of Cardiac PET technology products, this morning Positron's CEO Patrick G. Rooney surprised investors by telling them that the company's radiopharmaceuticals business may be getting more attention going forward as well. "While most in the industry already know that PET is the future of nuclear cardiology, we fully expect that an equal to greater amount of revenue and profits will be generated by our new proprietary automated radiopharmaceutical device as it is used in both the cardiac and oncology sectors."
AI
